Active surveillance for prostate cancer: Trials and tribulations

World Journal of Urology

Volumn 26, Issue 5, 2008, Pages 437-442

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Conservative management; Low risk disease; Prostate cancer; Review

Indexed keywords

ARTICLE; HEALTH SURVEY; HUMAN; MALE; PROSTATE TUMOR;

HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS;

EID: 53549099361     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0330-8     Document Type: Article

References (29)

1. Welch HG, Schwartz LM, Woloshin S (2005) Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal. J Natl Cancer Inst 97(15):1132-1137
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974
3. Albertsen P, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101
4. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J (2005) Prostate cancer and the Will Rogers phenomenon. Natl Cancer Inst 97:1248-1253
5. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ (2003) Lead times and overdetection due to PSA screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12):868-878
6. Tornblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, Hugosson J (2004) Lead time associated with screening for prostate cancer. Int J Cancer 108(1):122-129
7. Hanash K, Utz DC, Cook EN, Taylor WF, Titus JL (1972) Carcinoma of the prostate: A 15-year followup. J Urol 107:450-453
8. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277(6):467-471
9. Lerner SP, Seale-Hawkins C, Carlton CE Jr, Scardino PT (1991) The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146(4):1040-1045
10. Handley R, Carr TW, Travis D, Powell PH, Hall RR (1988) Deferred treatment for prostate cancer. Br J Urol 62(3):249-253
11. Adolfsson J, Carstensen J, Löwhagen T (1992) Deferred treatment in clinically localized prostate carcinoma. Brit J Urol 69:183-187
12. Waaler G, Stenwig AE (1993) Prognosis of localised prostatic cancer managed by "Watch and Wait" policy. Br J Urol 72:214-219
13. Whitmore W Jr, Warner JA, Thompson IM Jr (1991) Expectant management of localized prostatic cancer. Cancer 67:1091-1096
14. George N (1988) Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1(8584):494-497
15. Aus G, Hugosson I, Norlen L (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154:460-465
16. Sandblom G, Dufmats M, Varenhorst E (2000) Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 56:442-447
17. Parker C (2004) Active surveillance: Towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5:101-106
18. Parker C (2003) Active surveillance: An individualized approach to early prostate cancer. BJU Int 92:2-3
19. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G (2002) Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669
20. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G (2001) PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50:615-620
21. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE, Scandinavian Prostate Cancer Group Study No. 4 (2005) Radical prostatectomy versus watchful waiting (update). N Engl J Med 352(19):1977-1984
22. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J (2006) PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170-174
23. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M (2008) Active surveillance; a reasonable management alternative for patients with prostate cancer: The Miami experience. BJU Int 101(2):165-169
24. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI (2007) Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178(6):2359-2365
25. Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10):1361-1368
26. D'Amico AV, Chen MH, Roehl KA, Catalona WJ (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2):125-135
27. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F (2007) Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: A critical analysis of the literature. Eur Urol 52(5):1309-1322
28. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, Holmberg L, Scandinavian Prostatic Cancer Group Study Number 4 (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347(11):790-796
29. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M (2007) Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 100(3):540-543